These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 12711562)

  • 1. Treating congestive heart failure. The conclusion of a two-part series.
    Harv Mens Health Watch; 2003 Apr; 7(9):1-5. PubMed ID: 12711562
    [No Abstract]   [Full Text] [Related]  

  • 2. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart failure.
    McKelvie R
    Clin Evid; 2006 Jun; (15):118-39. PubMed ID: 16973007
    [No Abstract]   [Full Text] [Related]  

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [ACE inhibitor or ATII receptor blocker in heart failure and myocardial infarction?].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2005 Jan; 125(1):38-40. PubMed ID: 15643463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual renin-angiotensin system blockade in heart failure.
    McMurray JJ; Granger CB; Ostergren J; Yusuf S; Pfeffer MA; Swedberg K
    J Am Coll Cardiol; 2009 Jul; 54(3):278; author reply 279-80. PubMed ID: 19589444
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.
    Gotsman I; Rubonivich S; Azaz-Livshits T
    Isr Med Assoc J; 2008 Mar; 10(3):214-8. PubMed ID: 18494235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of combination angiotensin-converting enzyme and angiotensin receptor blocker therapy on heart failure mortality and morbidity.
    Kapoor JR
    Am J Cardiol; 2008 Mar; 101(5):744-5. PubMed ID: 18308033
    [No Abstract]   [Full Text] [Related]  

  • 9. The rationale and indications for angiotensin receptor blockers in heart failure.
    Bybee KA; Das S; O'Keefe JH
    Heart Fail Clin; 2006 Jan; 2(1):81-8. PubMed ID: 17386879
    [No Abstract]   [Full Text] [Related]  

  • 10. ACEI and ARB may also benefit CHF through immune system modulation (down-regulation of immune system).
    Fett JD
    Int J Cardiol; 2005 Aug; 103(1):107. PubMed ID: 16061132
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention of congestive heart failure in high risk patients.
    Wachtell K
    Eur Heart J; 2009 Mar; 30(6):638-9. PubMed ID: 19240069
    [No Abstract]   [Full Text] [Related]  

  • 12. Guidelines for atrial fibrillation in heart failure need to be clarified.
    Smit MD; Van Veldhuisen DJ; Van Gelder IC
    J Am Coll Cardiol; 2010 Jan; 55(2):167; author reply 168-9. PubMed ID: 20117387
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimal treatment of hypertension with diastolic heart failure.
    Susic D; Frohlich ED
    Heart Fail Clin; 2008 Jan; 4(1):117-24. PubMed ID: 18313629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic heart failure.
    Poole-Wilson PA
    Timely Top Med Cardiovasc Dis; 2007 Jan; 11():E2. PubMed ID: 18297148
    [No Abstract]   [Full Text] [Related]  

  • 15. [Is it always necessary to use triple combination in the treatment of patients with chronic cardiac failure? Choice of the third neurohormonal blocker].
    Belenkov IuN; Mareev VIu; Skvortsov AA
    Ter Arkh; 2008; 80(9):5-12. PubMed ID: 19555028
    [No Abstract]   [Full Text] [Related]  

  • 16. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H; Moukarbel GV; Dawson B; Hajjar RJ; Francis GS
    Am J Med; 2007 Dec; 120(12):1090.e1-8. PubMed ID: 18060931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of heart failure and preserved systolic function].
    Dahlström U; Boman K; Brodin LA; Hagerman I; Willenheimer R
    Lakartidningen; 2007 Aug 22-28; 104(34):2348-50. PubMed ID: 17907560
    [No Abstract]   [Full Text] [Related]  

  • 18. Sex differences in response to chronic heart failure therapies.
    Ghali JK; Lindenfeld J
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):555-65. PubMed ID: 18402544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
    Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract]   [Full Text] [Related]  

  • 20. Underuse of evidence-based therapies.
    Hlatky MA
    Circulation; 2004 Aug; 110(6):644-5. PubMed ID: 15302805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.